Skip to main content

Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.

Schindlbeck C, Stellwagen J, Jeschke U, Karsten U, Rack B, Janni W, Jückstock J, Tulusan A, Sommer H, Friese K

Publication: Clin Exp Metastasis (2008) • Vol 25 • Page 233-40PMID: 18185913View on PubMed

Purpose

This paper compared the percentage of bone marrow and peripheral blood specimens that were positive for disseminated tumor cells in the bone marrow (DTC-BM) and circulating tumor cells (CTCs), respectively, with and without immunomagnetic enrichment for cells expressing the Thomsen-Friedenreich antigen (CD176). Potential correlations between DTC and CTC status and tumor size, grading, lymph node status, estrogen or progesterone receptor status, or HER2-status were also explored.

Conclusion

Immunomagnetic enrichment of bone marrow specimens for CD176 expressing cells resulted in a significantly higher percentage of DTC-BM positive specimens and also nonsignificant increases in the mean number of white blood cells isolated per patient and relative number of DTC-BM detected per 106 white blood cells. Enrichment also resulted in a modest increase in the mean number of CTCs detected in peripheral blood specimens but lower relative CTC counts per 106 white blood cells. Overall concordance in DTC-BM and CTC status was 64% among the 11 patients examined. Importantly, no patients that were positive for CTCs were negative for DTC-BM. No significant correlation between DTC-BM or CTC counts after enrichment was observed for tumor size, grading, lymph node status, estrogen or progesterone receptor status, or HER2-status.

Studies (1)

Purpose

This study compared the percentage of bone marrow and peripheral blood specimens that were positive for DTCs and CTCs, respectively, with and without immunomagnetic enrichment of cells expressing the CD176 antigen. Potential correlations between DTC and CTC status and tumor size, grading, lymph node status, estrogen or progesterone receptor status, or HER2-status were also explored. Bone marrow specimens were collected by aspiration at anterior iliac crests (2–8 mL from each side) after general or local anesthesia was administered from 65 patients diagnosed with breast cancer and three patients diagnosed with a benign disease. Peripheral blood (~40 mL/patient) was collected in heparinized tubes from a subset of patients diagnosed with breast cancer (11 patients) and was processed within hours. White blood cells were isolated by Ficoll-Hypaque density gradient with centrifugation at 900 x g for 30 min. CD176-positive cells were enriched via magnetic separation and centrifugation. Cytospin slides were prepared, frozen, stained for cytokeratins by immunocytochemistry, and visualized by light microscopy. A specimen was considered positive if one cell, out of the 2 x 106 cells screened per specimen, stained positive for cytokeratins.

Summary of Findings

Immunomagnetic enrichment of bone marrow specimens for CD176-positive cells significantly increased the percentage of specimens that were DTC positive from 23% (15/65) to 72% (47/65) of breast cancer patients (P<0.0001) and resulted in nonsignificantincreases in both the mean number of white blood cells isolated per patient (from 2 x 106 to 2.3 x 107) and the relative number of DTC-BM detected per 106 cells (from 0.37 to 0.4; P=0.110). Immunomagnetic enrichment did not change the DTC-BM status of 25 of the 65 patients evaluated (38%); however, 36 patients that were DTC-BM negative during the primary screen were positive after enrichment (55%) and four patients that were DTC-BM positive during the primary screen were negative after enrichment (6%). Bone marrow collected from the three patients diagnosed with a benign disease were all DTC-BM negative, both before and after magnetic separation. Of the 11 blood specimens collected from breast cancer patients, immunomagnetic enrichment did not change the CTC status of six patients (55%); however, five patients that were CTC negative during the primary screen were positive after enrichment (45%) and one patient that was CTC positive during the primary screen was negative after enrichment (9%). Although not statistically significant, the mean number of CTCs detected in peripheral blood were higher after enrichment when compared to the preliminary screen (1.3 versus 0.2; P=0.1682) and the mean relative CTC count per 106 white blood cells was lower (0.06 versus 0.1; P=0.34). Without enrichment, 82% of patients (9/11) were negative for both DTC-BM and CTC, although one patient was positive for only DTC-BM and one for only CTC. After immunomagnetic enrichment, DTC-BM and CTC status had a concordance of 64% (7/11 patients), as four patients that were positive for DTC-BM were negative for CTC. Importantly, no patients that were CTC positive were DTC-BM negative. No significant correlation between DTC-BM or CTC count after enrichment was observed for tumor size, grading, lymph node status, estrogen or progesterone receptor status, or HER2-status.

  • Biospecimens

    CellBone Marrow
    FluidBlood
  • Preservation Types

    Other Preservative
  • Diagnoses

    Normal
    NeoplasticCarcinoma
  • Platforms

    Cell count/volumeLight microscopy
    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    HER2-status
    estrogen receptor status
    lymph node status
    progesterone receptor status
    tumor grading
    tumor size
    Biospecimen AcquisitionBiospecimen location
    bone marrow
    peripheral blood
    Biospecimen AcquisitionMethod of cell acquisition
    Immunomagnetic enrichment
    No enrichment
    Immunohistochemistry SpecificTargeted peptide/protein
    cytokeratins